Julie Daves

Julie Daves

SVP, Clinical Development OperationsatDiaMedica Therapeutics· In the 2023 proxy

Pay in FY2023DiaMedica Therapeutics stock +79.7% the same year

Julie Daves was paid $533.4K in FY2023 (Dec). DiaMedica Therapeutics stock rose 79.7% that year.

Pay$100 in the stock at the end of FY22 → $180
Pay is from the Summary Compensation Table of each DiaMedica Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. DiaMedica TherapeuticsPublic company · 3 yr
    • SVP, Clinical Development Operations2023 – Present · 3 yrStock in role +542%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?